[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345668-105":59,"doc-detail-345668-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","a-comprehensive-bioinformatic-analysis-of-slc52a3-as-a-prognostic-biomarker-and-potential-therapeutic-target-in-gynecological-cancers","A Comprehensive Bioinformatic Analysis of SLC52A3 as a Prognostic Biomarker and Potential Therapeutic Target in Gynecological Cancers","","The study examines SLC52A3, a riboflavin transporter gene, in gynecological cancers using integrated bioinformatic approaches across multi-omics resources. SLC52A3 expression is reported as elevated in ovarian, cervical, and endometrial cancers, while reduced expression aligns with poorer overall survival and shorter progression-free interval in endometrial cancer. Genetic alterations show no significant survival association, whereas enrichment and interaction analyses implicate roles in cell junction organization and plasma-membrane protein localization. Correlations connect SLC52A3 with tumor progression and metastasis-related genes. Results support its promise as a prognostic biomarker and therapeutic target.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-comprehensive-bioinformatic-analysis-of-slc52a3-as-a-prognostic-biomarker-and-potential-therapeutic-target-in-gynecological-cancers/345668/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-comprehensive-bioinformatic-analysis-of-slc52a3-as-a-prognostic-biomarker-and-potential-therapeutic-target-in-gynecological-cancers/345668.png","ImageObject",300,407,{"name":92,"@type":93},"River Wang","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the biological role of SLC52A3 addressed in this study?","Question",{"text":112,"@type":113},"SLC52A3 encodes riboflavin transporter-3, a transmembrane protein required for riboflavin absorption and for regulating tissue distribution of riboflavin.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does SLC52A3 expression relate to patient outcomes in endometrial cancer?",{"text":117,"@type":113},"Lower SLC52A3 expression is associated with poorer overall survival and a shorter progression-free interval specifically in endometrial cancer.",{"name":119,"@type":110,"acceptedAnswer":120},"Do SLC52A3 genetic alterations affect survival outcomes?",{"text":121,"@type":113},"Genetic alterations in SLC52A3, including mutations and copy number variations, are not significantly associated with survival outcomes such as OS, DFS, and PFS.",{"name":123,"@type":110,"acceptedAnswer":124},"What functional pathways and cellular processes are linked to SLC52A3?",{"text":125,"@type":113},"Functional enrichment indicates involvement in processes including cell junction organization and protein localization to the plasma membrane, and expression correlates with genes tied to tumor progression and metastasis.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},345668,1790920753,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":149,"preview_page_count":19,"preview_urls":150},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Article  \nA Comprehensive Bioinformatic Analysis of SLC52A3 as a Prognostic Biomarker and Potential Therapeutic Target in Gynecological Cancers  \nMonia Cecati 1,†, Valentina Schiavoni 2,†, Roberto Campagna 1, * and Giovanni Tossetta 1, *  \nAcademic Editor: Shefali Setia Verma  \nReceived: 24 April 2026  \nRevised: 29 May 2026  \nAccepted: 2 June 2026  \nPublished: 7 June 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department for the Promotion of Human Science and Quality of Life, San Raffaele Roma University, 00166 Rome, Italy; [monia.cecati@uniroma5.it](monia.cecati@uniroma5.it)  \n2 Department of Clinical Sciences, Polytechnic University of Marche, 60126 Ancona, Italy; [v.schiavoni@pm.univpm.it](v.schiavoni@pm.univpm.it)  \n* Correspondence: [roberto.campagna@uniroma5.it](roberto.campagna@uniroma5.it) (R.C.); [giovanni.tossetta@uniroma5.it](giovanni.tossetta@uniroma5.it) (G.T.)† These authors contributed equally to this work.  \nAbstract  \nBackground/Objectives: The gene solute carrier family 52 member 3 (SLC52A3) encodes riboflavin transporter-3, a transmembrane protein essential for riboflavin absorption. Emerging evidence suggests that metabolic transporters may play a role in tumor biology. This study aimed to investigate the expression patterns, prognostic significance, genetic alterations, and functional associations of SLC52A3 in gynecological cancers. Methods: A comprehensive bioinformatic analysis was conducted using multiomics datasets from The Cancer Genome Atlas (TCGA) . Gene expression and survival analyses were performed via GEPIA3 . Genetic alterations, including mutations and copy number variations, were assessed using cBioPortal. Immune infiltration correlations were analyzed through TIMER3 . Protein–protein interactions and gene enrichment analyses were performed using STRING and GEPIA2, followed by Gene Ontology (GO) and KEGG pathway analyses. Results: SLC52A3 expression was significantly upregulated in ovarian, cervical, and endometrial cancers. Reduced expression of SLC52A3 was associated with poorer overall survival and shorter progression-free interval specifically in endometrial cancer. Genetic alterations in SLC52A3 were not significantly associated with survival outcomes (OS, DFS, and PFS) . Functional enrichment analysis indicated that SLC52A3 is involved in biological processes such as cell junction organization and protein localization to the plasma membrane. Additionally, SLC52A3 expression showed positive correlations with genes implicated in tumor progression and metastasis, including NECTIN4, PROM2, TACSTD2, PKP3, SEMA4B, and CD46 . Conclusions: These findings suggest that SLC52A3 may serve as a potential prognostic biomarker in endometrial cancer and could play a role in tumor progression pathways. Its functional associations highlight its potential relevance as a therapeutic target, warranting further experimental validation.  \nKeywords: SLC52A3; riboflavin transporter; gynecological cancers; endometrial cancer; ovarian cancer; cervical cancer; prognostic biomarker; bioinformatics; TCGA; tumor microenvironment; immune infiltration; therapeutic target  \n1. Introduction  \nOver the past decade, multi-omics cancer datasets such as The Cancer Genome Atlas (TCGA) have been widely used in cancer research, enabling the understanding of the  \nmolecular mechanisms underlying many neoplasms [1] . Bioinformatic studies play a key role in cancer research since they allow to researchers to examine gene functions, mutations, expression profiles and survival outcomes in several malignancies. Consequently, these studies are important to find new genes that can be used as therapeutic targets in cancer treatment in order to improve the outcome of several malignancies.  \nGynecological cancers include six types of cancers: cervical, ovarian, uterine ","cbCaimSjT2NZOq9W","https://ap.wps.com/l/cbCaimSjT2NZOq9W","pdf",4021835,18,"English","# Abstract\n# 1. Introduction\n# 2. Materials and Methods","[{\"question\":\"What is the biological role of SLC52A3 addressed in this study?\",\"answer\":\"SLC52A3 encodes riboflavin transporter-3, a transmembrane protein required for riboflavin absorption and for regulating tissue distribution of riboflavin.\"},{\"question\":\"How does SLC52A3 expression relate to patient outcomes in endometrial cancer?\",\"answer\":\"Lower SLC52A3 expression is associated with poorer overall survival and a shorter progression-free interval specifically in endometrial cancer.\"},{\"question\":\"Do SLC52A3 genetic alterations affect survival outcomes?\",\"answer\":\"Genetic alterations in SLC52A3, including mutations and copy number variations, are not significantly associated with survival outcomes such as OS, DFS, and PFS.\"},{\"question\":\"What functional pathways and cellular processes are linked to SLC52A3?\",\"answer\":\"Functional enrichment indicates involvement in processes including cell junction organization and protein localization to the plasma membrane, and expression correlates with genes tied to tumor progression and metastasis.\"}]","A Comprehensive Bioinformatic Analysis of SLC52A3 as a Prognostic Biomarker and Potential Therapeutic Target in Gynecological Cancers | PDF",1790058515,45,[151,155,159,163],{"page_no":8,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4f2986030beba082d9b96c80e29b9d22.webp",983,1390,{"page_no":14,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1606d11c74538ce5005eb136b83b99b8.webp",982,1388,{"page_no":81,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20812b056d6270a48b0ad3396eb4fdfe.webp",981,1387,{"page_no":19,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20b188bd9dc4895707519c44a11d196b.webp",980,1385]